Intas Pharmaceuticals has signed an exclusive license and supply agreement with Axantia Holding, a leading pharmaceutical company in the Middle East operating through its pharmaceutical subsidiaries; Pharma International Pharmaceutical & Chemical Manufacturing Co. and Med City Pharmaceutical Industries for Ranibizumab (biosimilar of Lucentis). Under the terms of this agreement, Axantia will register, hold the marketing authorization and commercialize Ranibizumab in certain territories including Saudi Arabia, Jordan, Iraq, Lebanon and GCC countries.

Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US.

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Ranibizumab is indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularization (mCNV).